264 related articles for article (PubMed ID: 26016894)
1. Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.
Posch C; Cholewa BD; Vujic I; Sanlorenzo M; Ma J; Kim ST; Kleffel S; Schatton T; Rappersberger K; Gutteridge R; Ahmad N; Ortiz/Urda S
J Invest Dermatol; 2015 Oct; 135(10):2475-2483. PubMed ID: 26016894
[TBL] [Abstract][Full Text] [Related]
2. Playing Polo-Like Kinase in NRAS-Mutant Melanoma.
Chen HY; Villanueva J
J Invest Dermatol; 2015 Oct; 135(10):2352-2355. PubMed ID: 26358384
[TBL] [Abstract][Full Text] [Related]
3. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
Posch C; Moslehi H; Feeney L; Green GA; Ebaee A; Feichtenschlager V; Chong K; Peng L; Dimon MT; Phillips T; Daud AI; McCalmont TH; LeBoit PE; Ortiz-Urda S
Proc Natl Acad Sci U S A; 2013 Mar; 110(10):4015-20. PubMed ID: 23431193
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
[TBL] [Abstract][Full Text] [Related]
5.
Sanchez IM; Purwin TJ; Chervoneva I; Erkes DA; Nguyen MQ; Davies MA; Nathanson KL; Kemper K; Peeper DS; Aplin AE
Mol Cancer Ther; 2019 Sep; 18(9):1637-1648. PubMed ID: 31270153
[TBL] [Abstract][Full Text] [Related]
6. MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.
Vu HL; Rosenbaum S; Capparelli C; Purwin TJ; Davies MA; Berger AC; Aplin AE
J Invest Dermatol; 2016 Feb; 136(2):453-463. PubMed ID: 26967478
[TBL] [Abstract][Full Text] [Related]
7. Targeted knockdown of polo-like kinase 1 alters metabolic regulation in melanoma.
Gutteridge RE; Singh CK; Ndiaye MA; Ahmad N
Cancer Lett; 2017 May; 394():13-21. PubMed ID: 28235541
[TBL] [Abstract][Full Text] [Related]
8. Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells.
Cholewa BD; Pellitteri-Hahn MC; Scarlett CO; Ahmad N
J Proteome Res; 2014 Nov; 13(11):5041-50. PubMed ID: 24884503
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.
Kwong LN; Costello JC; Liu H; Jiang S; Helms TL; Langsdorf AE; Jakubosky D; Genovese G; Muller FL; Jeong JH; Bender RP; Chu GC; Flaherty KT; Wargo JA; Collins JJ; Chin L
Nat Med; 2012 Oct; 18(10):1503-10. PubMed ID: 22983396
[TBL] [Abstract][Full Text] [Related]
10. MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self Nanoclusters.
Yakovian O; Sajman J; Arafeh R; Neve-Oz Y; Alon M; Samuels Y; Sherman E
Cancer Res; 2021 Mar; 81(5):1279-1292. PubMed ID: 33355187
[TBL] [Abstract][Full Text] [Related]
11. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
[TBL] [Abstract][Full Text] [Related]
12. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
Stehle A; Hugle M; Fulda S
Cancer Lett; 2015 Aug; 365(1):37-46. PubMed ID: 25917079
[TBL] [Abstract][Full Text] [Related]
13. Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma.
Vu HL; Aplin AE
Mol Cancer Res; 2014 Oct; 12(10):1509-19. PubMed ID: 24962318
[TBL] [Abstract][Full Text] [Related]
14. PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.
Zuco V; De Cesare M; Zaffaroni N; Lanzi C; Cassinelli G
Oncotarget; 2015 Apr; 6(11):8736-49. PubMed ID: 25826089
[TBL] [Abstract][Full Text] [Related]
15. Involvement of polo-like kinase 1 (Plk1) in mitotic arrest by inhibition of mitogen-activated protein kinase-extracellular signal-regulated kinase-ribosomal S6 kinase 1 (MEK-ERK-RSK1) cascade.
Li R; Chen DF; Zhou R; Jia SN; Yang JS; Clegg JS; Yang WJ
J Biol Chem; 2012 May; 287(19):15923-34. PubMed ID: 22427657
[TBL] [Abstract][Full Text] [Related]
16. A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma.
Cai W; Nguyen MQ; Wilski NA; Purwin TJ; Vernon M; Tiago M; Aplin AE
Cancer Res; 2022 Jul; 82(14):2625-2639. PubMed ID: 35657206
[TBL] [Abstract][Full Text] [Related]
17. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
Kreis NN; Louwen F; Zimmer B; Yuan J
Oncotarget; 2015 Mar; 6(9):6611-26. PubMed ID: 25483104
[TBL] [Abstract][Full Text] [Related]
18. PLK1 and NOTCH Positively Correlate in Melanoma and Their Combined Inhibition Results in Synergistic Modulations of Key Melanoma Pathways.
Su S; Chhabra G; Ndiaye MA; Singh CK; Ye T; Huang W; Dewey CN; Setaluri V; Ahmad N
Mol Cancer Ther; 2021 Jan; 20(1):161-172. PubMed ID: 33177155
[TBL] [Abstract][Full Text] [Related]
19. Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells.
Eskandarpour M; Kiaii S; Zhu C; Castro J; Sakko AJ; Hansson J
Int J Cancer; 2005 May; 115(1):65-73. PubMed ID: 15688405
[TBL] [Abstract][Full Text] [Related]
20. Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs.
Hugle M; Belz K; Fulda S
Cell Death Differ; 2015 Dec; 22(12):1946-56. PubMed ID: 26024389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
